CareLit · DOI-Nachweis · Pneumologie
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials
DOI 10.1055/s-0036-1572063
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, L Lancaster, C Albera, WZ Bradford, EA Fagan, R Fishman, I Glaspole, MK Glassberg, TE King, DJ Lederer, Z Lin, SD Nathan, CA Pereira, JJ Swigris, D Valeyre, PW Noble
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Rationale: IPF is a chronic, progressive disease that requires long-term treatment. To evaluate the clinical safety of pirfenidone (PFD) in IPF, we performed a comprehensive integrated analysis of safety data from 5 clinical trials. Methods: All patients treated with PFD 2403 mg/d in the Phase 3 multinational studies (Ph.3: 004, 006, and 016) and all patients receiving at least one dose of PFD in the ongoing open-la…
Zitieren
Zitierempfehlung
U Costabel, L Lancaster, C Albera, WZ Bradford, EA Fagan, R Fishman, I Glaspole, MK Glassberg, TE King, DJ Lederer, Z Lin, SD Nathan, CA Pereira, JJ Swigris, D Valeyre, PW Noble (2016) Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials. Pneumologie (02). https://doi.org/10.1055/s-0036-1572063
Mit CareLit weiterarbeiten